相似文献
1
PAX3-FKHR sensitizes human alveolar rhabdomyosarcoma cells to camptothecin-mediated growth inhibition and apoptosis.
Cancer Lett. 2009 Nov 1;284(2):157-64. doi: 10.1016/j.canlet.2009.04.016. Epub 2009 May 12.
2
Glycogen synthase kinase 3 regulates PAX3-FKHR-mediated cell proliferation in human alveolar rhabdomyosarcoma cells.
Biochem Biophys Res Commun. 2010 Jan 1;391(1):1049-55. doi: 10.1016/j.bbrc.2009.12.017. Epub 2009 Dec 6.
3
Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
Cancer Res. 2006 May 1;66(9):4742-9. doi: 10.1158/0008-5472.CAN-05-4292.
4
Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma.
Clin Cancer Res. 2015 Nov 1;21(21):4868-80. doi: 10.1158/1078-0432.CCR-14-1797. Epub 2015 Jun 12.
5
6
Nephroblastoma overexpressed (NOV/CCN3) gene: a paired-domain-specific PAX3-FKHR transcription target that promotes survival and motility in alveolar rhabdomyosarcoma cells.
Oncogene. 2011 Aug 11;30(32):3549-62. doi: 10.1038/onc.2011.69. Epub 2011 Mar 21.
7
Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
J Pathol. 2007 Jun;212(2):143-51. doi: 10.1002/path.2170.
8
Structural and functional studies of FKHR-PAX3, a reciprocal fusion gene of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma.
PLoS One. 2013 Jun 14;8(6):e68065. doi: 10.1371/journal.pone.0068065. Print 2013.
9
Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target.
Genes Chromosomes Cancer. 2008 Jun;47(6):510-20. doi: 10.1002/gcc.20554.
10
FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma.
J Cell Biol. 2005 Sep 12;170(6):903-12. doi: 10.1083/jcb.200501040.
引用本文的文献
1
Role of FoxO Proteins in Cellular Response to Antitumor Agents.
Cancers (Basel). 2019 Jan 14;11(1):90. doi: 10.3390/cancers11010090.
2
Camptothecin exhibits topoisomerase1-independent KMT1A suppression and myogenic differentiation in alveolar rhabdomyosarcoma cells.
Oncotarget. 2018 May 25;9(40):25796-25807. doi: 10.18632/oncotarget.25376.
3
HNRNPH1 is required for rhabdomyosarcoma cell growth and survival.
Oncogenesis. 2018 Jan 24;7(1):9. doi: 10.1038/s41389-017-0024-4.
4
Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models.
Neoplasia. 2017 Jun;19(6):460-470. doi: 10.1016/j.neo.2017.03.004. Epub 2017 May 8.
5
Regulation of Nuclear Receptor Nur77 by miR-124.
PLoS One. 2016 Feb 3;11(2):e0148433. doi: 10.1371/journal.pone.0148433. eCollection 2016.
6
PAX3-FKHR regulates the expression of pleiotrophin to mediate motility in alveolar rhabdomyosarcoma cells.
J Can Res Updates. 2012 Jan 1;1(1). doi: 10.6000/1929-2279.2012.01.01.09.
7
The antiapoptotic function of miR-96 in prostate cancer by inhibition of FOXO1.
PLoS One. 2013 Nov 19;8(11):e80807. doi: 10.1371/journal.pone.0080807. eCollection 2013.
8
Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma.
Mol Cancer Ther. 2013 Dec;12(12):2663-74. doi: 10.1158/1535-7163.MCT-13-0277. Epub 2013 Oct 9.
9
Cyclin-dependent kinase 4 phosphorylates and positively regulates PAX3-FOXO1 in human alveolar rhabdomyosarcoma cells.
PLoS One. 2013;8(2):e58193. doi: 10.1371/journal.pone.0058193. Epub 2013 Feb 28.
10
A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma.
Expert Opin Ther Targets. 2013 May;17(5):607-23. doi: 10.1517/14728222.2013.772136. Epub 2013 Feb 25.
本文引用的文献
1
Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy.
Nature. 2008 Oct 30;455(7217):1205-9. doi: 10.1038/nature07284. Epub 2008 Sep 17.
2
Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells.
J Biol Chem. 2008 Nov 7;283(45):30650-7. doi: 10.1074/jbc.M806132200. Epub 2008 Sep 9.
3
PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma.
Oncogene. 2008 Nov 20;27(51):6550-60. doi: 10.1038/onc.2008.255. Epub 2008 Aug 4.
4
Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities.
Cancer Res. 2008 May 15;68(10):3767-76. doi: 10.1158/0008-5472.CAN-07-2447.
5
PAX3-FOXO1 fusion gene in rhabdomyosarcoma.
Cancer Lett. 2008 Oct 18;270(1):10-8. doi: 10.1016/j.canlet.2008.03.035. Epub 2008 May 23.
6
A cell-microelectronic sensing technique for profiling cytotoxicity of chemicals.
Anal Chim Acta. 2008 May 12;615(1):80-7. doi: 10.1016/j.aca.2008.03.047. Epub 2008 Apr 1.
7
Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor.
Cell Cycle. 2008 Apr 1;7(7):837-41. doi: 10.4161/cc.7.7.5652. Epub 2008 Jan 22.
8
Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma.
Eur J Cancer. 2008 Apr;44(6):876-84. doi: 10.1016/j.ejca.2008.02.022. Epub 2008 Mar 14.
9
Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target.
Genes Chromosomes Cancer. 2008 Jun;47(6):510-20. doi: 10.1002/gcc.20554.
10
Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma.
Biochem Biophys Res Commun. 2008 Jan 18;365(3):568-74. doi: 10.1016/j.bbrc.2007.11.017. Epub 2007 Nov 20.
Zotero 插件